The study demonstrated efficacy in the treated patients based on increase cardiac muscle contraction ability as compared to patients that had bypass surgery but did not receive stem cells.
In a recent paper the use of mesenchymal stem cells was evaluated after the cells have been stored frozen.
A paper published today from the Mary Laughlin's group describes the use of cord blood cells in creation of new blood vessels.
NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
Today NOXXON announced that is has successfully administered its NOX-A12 aptamer-based mobilizer to healthy volunteers as part of a Phase I clinical trial.
The adult stem cell company Aldagen Inc, from Durham North Carolina announced today that it has filed a registration with the Securities Exchange Commission for an initial public offering with a potential value of $80.5 million.
In yet another heart disease study, adult stem cells derived from adipose tissue are chosen as the most promising therapy.
The U.S. adult stem cell company Bioheart has announced positive results from its clinical trial in the treatment of heart failure with adult stem cells.
Among this year's recipients of the Lasker Awards are Dr. Shinya Yamanaka of Kyoto University in Japan and Dr. John Gurdon of Cambridge University in England.
The U.S. company Neuralstem receives yet another patent for its novel adult stem cell technology.
The adult stem cell company Cardio3 BioSciences presents an update on its heart failure therapy at the annual conference of the European Society of Cardiology.